TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 19nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 21nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 23nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 25nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 29nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 31nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 34nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 34.7nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 34.8nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 35nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 35nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 36nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 40nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 47nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 52nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 59nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 60nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 64nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 66nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 72.1nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 105nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 107nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 110nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 116nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 116nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 119nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 119nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 121nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 137nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 156nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 162nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 177nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 178nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 182nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 197nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 203nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand Info